AU2003259995B2 - Compositions and methods for treating cardiovascular disease - Google Patents

Info

Publication number

AU2003259995B2

AU2003259995B2 AU2003259995A AU2003259995A AU2003259995B2 AU 2003259995 B2 AU2003259995 B2 AU 2003259995B2 AU 2003259995 A AU2003259995 A AU 2003259995A AU 2003259995 A AU2003259995 A AU 2003259995A AU 2003259995 B2 AU2003259995 B2 AU 2003259995B2

Authority

AU

Australia

Prior art keywords

antagonists

antagonist

polypeptide

receptor

soluble

Prior art date

2002-08-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 110
• 208000024172 Cardiovascular disease Diseases 0.000 title claims description 71
• 239000000203 mixture Substances 0.000 title description 44
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 208
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 208
• 239000005557 antagonist Substances 0.000 claims description 163
• 241000282414 Homo sapiens Species 0.000 claims description 35
• 238000011282 treatment Methods 0.000 claims description 30
• 150000001875 compounds Chemical class 0.000 claims description 25
• 108060003951 Immunoglobulin Proteins 0.000 claims description 20
• 102000018358 immunoglobulin Human genes 0.000 claims description 20
• 239000003814 drug Substances 0.000 claims description 19
• 108010082808 4-1BB Ligand Proteins 0.000 claims description 17
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 17
• 230000002757 inflammatory effect Effects 0.000 claims description 16
• 102000004127 Cytokines Human genes 0.000 claims description 14
• 108090000695 Cytokines Proteins 0.000 claims description 14
• 239000003446 ligand Substances 0.000 claims description 13
• 230000006907 apoptotic process Effects 0.000 claims description 12
• 230000000747 cardiac effect Effects 0.000 claims description 12
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 11
• 230000003042 antagnostic effect Effects 0.000 claims description 8
• 239000012730 sustained-release form Substances 0.000 claims description 6
• 208000009525 Myocarditis Diseases 0.000 claims description 5
• 229940079593 drug Drugs 0.000 claims description 5
• 238000002347 injection Methods 0.000 claims description 4
• 239000007924 injection Substances 0.000 claims description 4
• 208000010125 myocardial infarction Diseases 0.000 claims description 4
• 230000001105 regulatory effect Effects 0.000 claims description 3
• 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
• 206010061216 Infarction Diseases 0.000 claims description 2
• 206010028980 Neoplasm Diseases 0.000 claims description 2
• 239000002246 antineoplastic agent Substances 0.000 claims description 2
• 239000007943 implant Substances 0.000 claims description 2
• 230000007574 infarction Effects 0.000 claims description 2
• 230000002685 pulmonary effect Effects 0.000 claims description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 claims 4
• 102000002627 4-1BB Ligand Human genes 0.000 claims 2
• 206010048610 Cardiotoxicity Diseases 0.000 claims 2
• 206010003119 arrhythmia Diseases 0.000 claims 2
• 231100000259 cardiotoxicity Toxicity 0.000 claims 2
• 208000008494 pericarditis Diseases 0.000 claims 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
• 239000005541 ACE inhibitor Substances 0.000 claims 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
• 229940035676 analgesics Drugs 0.000 claims 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
• 239000000730 antalgic agent Substances 0.000 claims 1
• 230000003110 anti-inflammatory effect Effects 0.000 claims 1
• 230000036772 blood pressure Effects 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 229960000975 daunorubicin Drugs 0.000 claims 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 229960001904 epirubicin Drugs 0.000 claims 1
• 210000005003 heart tissue Anatomy 0.000 claims 1
• 229960000908 idarubicin Drugs 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 claims 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
• 150000003431 steroids Chemical class 0.000 claims 1
• 230000009885 systemic effect Effects 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 279
• 102000004196 processed proteins & peptides Human genes 0.000 description 239
• 108050003558 Interleukin-17 Proteins 0.000 description 233
• 102000013691 Interleukin-17 Human genes 0.000 description 232
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 220
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 219
• 229920001184 polypeptide Polymers 0.000 description 215
• 108090000171 Interleukin-18 Proteins 0.000 description 211
• 102000003810 Interleukin-18 Human genes 0.000 description 210
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 209
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 209
• 102000004554 Interleukin-17 Receptors Human genes 0.000 description 175
• 108010017525 Interleukin-17 Receptors Proteins 0.000 description 173
• 108010017987 CD30 Ligand Proteins 0.000 description 163
• 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 163
• 102000004473 OX40 Ligand Human genes 0.000 description 151
• 108010042215 OX40 Ligand Proteins 0.000 description 151
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 149
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 145
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 143
• 102000004557 Interleukin-18 Receptors Human genes 0.000 description 136
• 108010017537 Interleukin-18 Receptors Proteins 0.000 description 136
• 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 129
• 108010070145 interleukin-18 binding protein Proteins 0.000 description 100
• 102000044166 interleukin-18 binding protein Human genes 0.000 description 100
• 235000001014 amino acid Nutrition 0.000 description 96
• 230000027455 binding Effects 0.000 description 90
• 229940024606 amino acid Drugs 0.000 description 87
• 150000001413 amino acids Chemical class 0.000 description 85
• 108090000623 proteins and genes Proteins 0.000 description 81
• 210000004027 cell Anatomy 0.000 description 66
• 102000004169 proteins and genes Human genes 0.000 description 66
• 235000018102 proteins Nutrition 0.000 description 55
• 230000004071 biological effect Effects 0.000 description 53
• 125000003275 alpha amino acid group Chemical group 0.000 description 47
• 239000012634 fragment Substances 0.000 description 43
• 238000006467 substitution reaction Methods 0.000 description 41
• 125000000539 amino acid group Chemical group 0.000 description 39
• -1 4-lBB Proteins 0.000 description 37
• 238000003556 assay Methods 0.000 description 37
• 230000003993 interaction Effects 0.000 description 33
• 108091033319 polynucleotide Proteins 0.000 description 33
• 102000040430 polynucleotide Human genes 0.000 description 33
• 239000002157 polynucleotide Substances 0.000 description 33
• 230000000694 effects Effects 0.000 description 32
• 238000004519 manufacturing process Methods 0.000 description 28
• 102000005962 receptors Human genes 0.000 description 28
• 108020003175 receptors Proteins 0.000 description 28
• 108020001507 fusion proteins Proteins 0.000 description 27
• 102000037865 fusion proteins Human genes 0.000 description 27
• 230000014509 gene expression Effects 0.000 description 27
• 230000004927 fusion Effects 0.000 description 26
• 230000003213 activating effect Effects 0.000 description 24
• 210000001744 T-lymphocyte Anatomy 0.000 description 23
• 150000007523 nucleic acids Chemical class 0.000 description 23
• 239000002773 nucleotide Substances 0.000 description 23
• 125000003729 nucleotide group Chemical group 0.000 description 23
• 230000004913 activation Effects 0.000 description 22
• 108020004999 messenger RNA Proteins 0.000 description 20
• 239000000816 peptidomimetic Substances 0.000 description 18
• 230000002401 inhibitory effect Effects 0.000 description 17
• 241000699670 Mus sp. Species 0.000 description 16
• 102000039446 nucleic acids Human genes 0.000 description 16
• 108020004707 nucleic acids Proteins 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 15
• 108091028043 Nucleic acid sequence Proteins 0.000 description 15
• 108010076504 Protein Sorting Signals Proteins 0.000 description 15
• 230000004044 response Effects 0.000 description 15
• 230000001225 therapeutic effect Effects 0.000 description 15
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 14
• 108090000994 Catalytic RNA Proteins 0.000 description 13
• 102000053642 Catalytic RNA Human genes 0.000 description 13
• 239000002202 Polyethylene glycol Substances 0.000 description 13
• 238000009396 hybridization Methods 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 229920001223 polyethylene glycol Polymers 0.000 description 13
• 108091092562 ribozyme Proteins 0.000 description 13
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
• 229940009456 adriamycin Drugs 0.000 description 12
• 239000012528 membrane Substances 0.000 description 12
• 210000004379 membrane Anatomy 0.000 description 12
• 230000035755 proliferation Effects 0.000 description 12
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
• 230000000295 complement effect Effects 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 230000037430 deletion Effects 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 238000013519 translation Methods 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 10
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• 230000000692 anti-sense effect Effects 0.000 description 10
• 210000002216 heart Anatomy 0.000 description 10
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 230000004957 immunoregulator effect Effects 0.000 description 9
• 125000005647 linker group Chemical group 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000012986 modification Methods 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 9
• 230000011664 signaling Effects 0.000 description 9
• 108010007730 Apyrase Proteins 0.000 description 8
• 102000007347 Apyrase Human genes 0.000 description 8
• 206010019280 Heart failures Diseases 0.000 description 8
• 239000002299 complementary DNA Substances 0.000 description 8
• 230000001086 cytosolic effect Effects 0.000 description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 238000003780 insertion Methods 0.000 description 8
• 230000037431 insertion Effects 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 230000003278 mimic effect Effects 0.000 description 8
• 229920000642 polymer Polymers 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 230000000770 proinflammatory effect Effects 0.000 description 8
• 108010074051 C-Reactive Protein Proteins 0.000 description 7
• 102100032752 C-reactive protein Human genes 0.000 description 7
• 229920002307 Dextran Polymers 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 7
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
• 230000002378 acidificating effect Effects 0.000 description 7
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
• 230000000903 blocking effect Effects 0.000 description 7
• 238000012512 characterization method Methods 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000036470 plasma concentration Effects 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 238000012216 screening Methods 0.000 description 7
• 150000003384 small molecules Chemical class 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 6
• 108020005544 Antisense RNA Proteins 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 6
• 102100035010 Interleukin-18 receptor accessory protein Human genes 0.000 description 6
• 101710138729 Interleukin-18 receptor accessory protein Proteins 0.000 description 6
• 230000004988 N-glycosylation Effects 0.000 description 6
• 108010067902 Peptide Library Proteins 0.000 description 6
• 230000004075 alteration Effects 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 210000000170 cell membrane Anatomy 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 239000003184 complementary RNA Substances 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 201000010099 disease Diseases 0.000 description 6
• 230000004064 dysfunction Effects 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 230000000302 ischemic effect Effects 0.000 description 6
• 238000002955 isolation Methods 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
• XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 5
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 5
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 241001529936 Murinae Species 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 208000007536 Thrombosis Diseases 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 210000000612 antigen-presenting cell Anatomy 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 239000000539 dimer Substances 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 102000043959 human IL18 Human genes 0.000 description 5
• 102000050320 human TNFRSF4 Human genes 0.000 description 5
• 239000000017 hydrogel Substances 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
• 230000003827 upregulation Effects 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 4
• 102000013602 Cardiac Myosins Human genes 0.000 description 4
• 108010051609 Cardiac Myosins Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 4
• 108090001005 Interleukin-6 Proteins 0.000 description 4
• 102000004889 Interleukin-6 Human genes 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 4
• 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 4
• 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 230000009368 gene silencing by RNA Effects 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 238000000099 in vitro assay Methods 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 239000002777 nucleoside Substances 0.000 description 4
• 235000021317 phosphate Nutrition 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000002463 transducing effect Effects 0.000 description 4
• 239000013598 vector Substances 0.000 description 4
• 229920003169 water-soluble polymer Polymers 0.000 description 4
• 206010002388 Angina unstable Diseases 0.000 description 3
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
• 229940082465 CD30 antagonist Drugs 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 102000003952 Caspase 3 Human genes 0.000 description 3
• 108090000397 Caspase 3 Proteins 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 102000009109 Fc receptors Human genes 0.000 description 3
• 108010087819 Fc receptors Proteins 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 3
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 108090001007 Interleukin-8 Proteins 0.000 description 3
• 102000004890 Interleukin-8 Human genes 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 208000007814 Unstable Angina Diseases 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 238000004590 computer program Methods 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 230000000139 costimulatory effect Effects 0.000 description 3
• 230000016396 cytokine production Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• 238000005538 encapsulation Methods 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 230000030279 gene silencing Effects 0.000 description 3
• 238000012226 gene silencing method Methods 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 125000001165 hydrophobic group Chemical group 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 210000004165 myocardium Anatomy 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 238000006384 oligomerization reaction Methods 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 238000007423 screening assay Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• 238000010532 solid phase synthesis reaction Methods 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 230000002459 sustained effect Effects 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• 108020004491 Antisense DNA Proteins 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 206010064539 Autoimmune myocarditis Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
• 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
• 102100029725 Ectonucleoside triphosphate diphosphohydrolase 3 Human genes 0.000 description 2
• 102100036437 Ectonucleoside triphosphate diphosphohydrolase 6 Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101001012432 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 3 Proteins 0.000 description 2
• 101000851972 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 6 Proteins 0.000 description 2
• 101000851976 Homo sapiens Nucleoside diphosphate phosphatase ENTPD5 Proteins 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102000003505 Myosin Human genes 0.000 description 2
• 108060008487 Myosin Proteins 0.000 description 2
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
• 102100036518 Nucleoside diphosphate phosphatase ENTPD5 Human genes 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 241000251131 Sphyrna Species 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 239000011149 active material Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 238000012867 alanine scanning Methods 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 150000001408 amides Chemical group 0.000 description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 239000003816 antisense DNA Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 238000006664 bond formation reaction Methods 0.000 description 2
• 238000004422 calculation algorithm Methods 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 210000004413 cardiac myocyte Anatomy 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000001516 cell proliferation assay Methods 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 238000004163 cytometry Methods 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 125000004185 ester group Chemical group 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 230000004217 heart function Effects 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 230000002439 hemostatic effect Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 102000054539 human TNFSF8 Human genes 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 210000002570 interstitial cell Anatomy 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 230000010118 platelet activation Effects 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 150000004804 polysaccharides Chemical class 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 238000004153 renaturation Methods 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 102220080600 rs797046116 Human genes 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 239000013638 trimer Substances 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 230000007730 Akt signaling Effects 0.000 description 1
• WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
• NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
• IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 241001156002 Anthonomus pomorum Species 0.000 description 1
• 102000013918 Apolipoproteins E Human genes 0.000 description 1
• 108010025628 Apolipoproteins E Proteins 0.000 description 1
• 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
• JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
• KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
• IQTUDDBANZYMAR-WDSKDSINSA-N Asn-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O IQTUDDBANZYMAR-WDSKDSINSA-N 0.000 description 1
• FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000007204 Brain death Diseases 0.000 description 1
• 241001598984 Bromius obscurus Species 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 102000001902 CC Chemokines Human genes 0.000 description 1
• 108010040471 CC Chemokines Proteins 0.000 description 1
• 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
• 229940122371 CD39 antagonist Drugs 0.000 description 1
• 108010080422 CD39 antigen Proteins 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 108050006947 CXC Chemokine Proteins 0.000 description 1
• 102000019388 CXC chemokine Human genes 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100161935 Caenorhabditis elegans act-4 gene Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
• 102000000018 Chemokine CCL2 Human genes 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• 101001023124 Drosophila melanogaster Myosin heavy chain, non-muscle Proteins 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 101150064015 FAS gene Proteins 0.000 description 1
• 108010039471 Fas Ligand Protein Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 108091006054 His-tagged proteins Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
• 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• TUYOFUHICRWDGA-CIUDSAMLSA-N Ile-Met Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCSC TUYOFUHICRWDGA-CIUDSAMLSA-N 0.000 description 1
• 235000003332 Ilex aquifolium Nutrition 0.000 description 1
• 241000209027 Ilex aquifolium Species 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
• FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
• 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
• 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
• 208000020128 Mitral stenosis Diseases 0.000 description 1
• 206010027727 Mitral valve incompetence Diseases 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
• 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
• 101001055215 Mus musculus Interleukin-9 Proteins 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 101150012195 PREB gene Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 1
• KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920000037 Polyproline Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
• 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
• QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
• DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 101800001707 Spacer peptide Proteins 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 1
• 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 1
• 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
• 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
• 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
• 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 210000000447 Th1 cell Anatomy 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
• 206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
• ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
• 208000024248 Vascular System injury Diseases 0.000 description 1
• 208000012339 Vascular injury Diseases 0.000 description 1
• 208000012346 Venoocclusive disease Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000006786 activation induced cell death Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
• LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 108010068380 arginylarginine Proteins 0.000 description 1
• 108010062796 arginyllysine Proteins 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 230000036523 atherogenesis Effects 0.000 description 1
• 208000028535 bacterial myocarditis Diseases 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 210000005242 cardiac chamber Anatomy 0.000 description 1
• 230000003683 cardiac damage Effects 0.000 description 1
• 206010007625 cardiogenic shock Diseases 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
• 230000010267 cellular communication Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 238000003568 cytokine secretion assay Methods 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000002592 echocardiography Methods 0.000 description 1
• 108010047482 ectoATPase Proteins 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 230000020764 fibrinolysis Effects 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 238000011990 functional testing Methods 0.000 description 1
• 230000000799 fusogenic effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 102000043557 human IFNG Human genes 0.000 description 1
• 102000049885 human IL11 Human genes 0.000 description 1
• 102000052627 human IL9 Human genes 0.000 description 1
• 229940116886 human interleukin-6 Drugs 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 201000007119 infective endocarditis Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000035992 intercellular communication Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 229960001375 lactose Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000003526 lymphopoietic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 208000006887 mitral valve stenosis Diseases 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 230000009149 molecular binding Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 108700024542 myc Genes Proteins 0.000 description 1
• 230000003680 myocardial damage Effects 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000004296 naive t lymphocyte Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 230000023837 negative regulation of proteolysis Effects 0.000 description 1
• 108091027963 non-coding RNA Proteins 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
• 230000003606 oligomerizing effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 229940126701 oral medication Drugs 0.000 description 1
• 239000008184 oral solid dosage form Substances 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 108010026466 polyproline Proteins 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 229920013730 reactive polymer Polymers 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 230000014176 regulation of innate immune response Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000020874 response to hypoxia Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000002702 ribosome display Methods 0.000 description 1
• 238000002821 scintillation proximity assay Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 208000037905 systemic hypertension Diseases 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 230000002537 thrombolytic effect Effects 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 206010047470 viral myocarditis Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1